| 前收市價 | 44.33 |
| 開市 | 47.05 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 47.05 - 47.05 |
| 52 週波幅 | 34.33 - 49.86 |
| 成交量 | |
| 平均成交量 | 155 |
| 市值 | 13.805B |
| Beta 值 (5 年，每月) | 0.90 |
| 市盈率 (最近 12 個月) | 26.28 |
| 每股盈利 (最近 12 個月) | 1.79 |
| 業績公佈日 | 2024年7月30日 |
| 遠期股息及收益率 | 1.28 (2.73%) |
| 除息日 | 2024年5月17日 |
| 1 年預測目標價 | 無 |
- Reuters
Fresenius Medical sees up to 2% US dialysis growth by year-end
The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the pandemic on patients fades. Fresenius Medical Care is the world's largest kidney dialysis company, and the fallout from the pandemic - which led to an increase in deaths among patients - has weighed heavily on its shares. Fresenius Medical earlier this year said it anticipated a return to treatment volume growth in the U.S. over the course of 2024, as it slowly recovers from COVID-related deaths among its patients, many of whom suffer from a range of cardiovascular conditions.
Insider MonkeyFresenius Medical Care AG & Co. KGaA (NYSE:FMS) Q1 2024 Earnings Call Transcript
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Q1 2024 Earnings Call Transcript May 7, 2024 Fresenius Medical Care AG & Co. KGaA beats earnings expectations. Reported EPS is $0.36, expectations were $0.26. Fresenius Medical Care AG & Co. KGaA isn’t one of the 30 most popular stocks among hedge funds at the end of […]
ZacksFresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up
Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
